盤龍藥業(002864.SZ):擬與關天資本共同發起設立陝西秦龍藥康投資基金
格隆匯11月29日丨盤龍藥業(002864.SZ)公佈,公司為進一步落實產業佈局,深入踐行守正創新的產業升級路徑,夯實公司核心競爭力,實現“一體兩翼”戰略目標,擬與陝西關天資本管理有限公司(簡稱“關天資本”)共同發起設立陝西秦龍藥康投資合夥企業(有限合夥)(暫定名,以工商部門核准名稱為準,簡稱“基金”)。
基金總規模不超過2億元人民幣,其中公司作為有限合夥人出資不高於4000萬元,且不超過基金最終總出資額的20%,關天資本或其子公司及關聯方作為有限合夥人出資不低於1000萬元,剩餘資金由政府引導基金及其他社會資本方進行出資。關天資本旗下具有私募股權基金管理人資格的子公司西安關天創新投資管理有限公司(簡稱“關天創新”)擔任本基金的普通合夥人、執行事務合夥人及基金管理人。
基金投資方向:基金實繳規模70%以上主要圍繞醫藥行業創新類項目。包括但不限於以創新藥及其產業鏈、骨科領域創新產品或技術、高端醫療器械、細胞免疫療法、基因免疫療法等。投資方式採取股權投資的投資方式,可根據不同的投資對象,在適用法律可行的範圍內,採取不同的投資形式。包括但不限於合夥企業設立合夥企業、公司等特殊目的載體,通過合夥企業、公司等特殊目的載體進行間接投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.